Can a new drug outperform standard care for a rare liver disease in teens?
Disease control
Terminated
This phase 2 trial is testing whether an experimental drug called HTD1801 can improve liver health in adolescents with primary sclerosing cholangitis (PSC), a rare disease that damages the bile ducts. Participants will receive either HTD1801 or the standard treatment, ursodeoxych…
Phase: PHASE2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC